Join us at the inaugural scientific symposium organised by the Consortium for Clinical Research and Innovation, Singapore (CRIS) on Wed 6 April 2022. Delve into the future of clinical research and healthcare innovation with topics such as Singapore’s National Precision Medicine strategy, leading-edge cell therapy technologies, how to enable sustainability in cancer research, and catalyse clinical research and innovation through national platforms.
A new national consortium – the Consortium for Clinical Research and Innovation, Singapore (CRIS) – has been officially launched by the Minister for Health Mr Ong Ye Kung on 6 April 2022 CRIS brings together five key national R&D, clinical translation and service initiatives that will advance clinical research and innovation for Singapore, and establish important capabilities for a future-ready healthcare system
Singapore Translational Cancer Consortium, National Cancer Centre Singapore, National University Hospital and Roche signed a Memorandum of Understanding (MOU) to leverage data insights and deepen understanding of unique drivers of disease to help improve health outcomes
Biomedical research is overseen by numerous Institutional Review Boards (IRBs) in Singapore but there has been no research that examines how the research review process is perceived by the local research community nor is there any systematic data on perceptions regarding the review process or other research ethics processes and IRB characteristics.
This expert opinion review examines the key challenges to the clinical adoption of NGS-based diagnostics in Singapore, provides recommendations on impactful initiatives to improve adoption, and also offers practical guidance on specific cancer types in which NGS-based diagnostics are appropriate for use in Singapore.